Why Sarepta Therapeutics Stock Is Skyrocketing Today
Shares of Sarepta Therapeutics (NASDAQ: SRPT) were skyrocketing 24.9% higher as of 10:37 a.m. ET on Monday. The huge gain came after the company announced Friday evening that a U.S. Food and Drug Administration (FDA) advisory committee voted in support of accelerated approval of SRP-9001 in treating Duchenne muscular dystrophy (DMD).
Sarepta said that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 8-6 in favor of approving SRP-9001. DMD is caused by genetic mutations that prevent the production of the dystrophin protein. SRP-9001 is a gene therapy that's designed to correct this underlying genetic issue and help produce dystrophin in the muscle tissue.
An 8-6 vote might seem really close. However, the bottom line is that Sarepta got the positive advisory committee recommendation that it needed.
Source Fool.com
Sarepta Therapeutics Aktie
Die Sarepta Therapeutics Aktie steht noch am Anfang: Zu wenige Einschätzungen für ein Sentiment.
Ein positives, wenn auch bescheidenes, Potenzial für Sarepta Therapeutics mit einem Kursziel von 130 € im Vergleich zum aktuellen Kurs von 128.45 €.
